The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...

On Wednesday, a jury in Cook County Circuit Court in Illinois ended in a mistrial in a case against Zantac manufacturer ...

Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

The trial met its primary endpoint, showing a meaningful objective response rate and a tolerable safety profile for ...

The recent trial regarding the discontinued heartburn drug Zantac, which allegedly causes cancer, ended in a hung jury. The ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...

A Chicago jury failed to reach a verdict in the latest Zantac cancer trial involving Boehringer Ingelheim. Plaintiff Ronald ...

Boehringer Ingelheim today announced that the FIBRONEER-IPF trial met its primary endpoint, which was the absolute change ...

Boehringer Ingelheim pivotal phase-III FIBRONEER-IPF study of nerandomilast meets primary endpoint: Ingelheim, Germany Tuesday, September 17, 2024, 13:00 Hrs [IST] Boehringer Inge ...

The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for Biomedical Artificial Intelligence (AI) based on a € 150 million funding from the ...